Patents Assigned to Pharma Mar, S.A.U.
  • Kahalalide compositions
    Patent number: 7683028
    Abstract: The present invention is directed to new kahalalide antitumoral compounds, in particular to analogs of kahalalide F, useful as antitumoral, antiviral, and antifungal agents.
    Type: Grant
    Filed: January 25, 2008
    Date of Patent: March 23, 2010
    Assignee: Pharma Mar, S.A.U.
    Inventors: Glynn Thomas Faircloth, Maria del Carmen Cuevas Marchante
  • Combination of ET-743 and a 5-fluorouracil pro-drug for cancer treatment
    Patent number: 7622458
    Abstract: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/m2 for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.
    Type: Grant
    Filed: November 15, 2004
    Date of Patent: November 24, 2009
    Assignee: Pharma Mar, S.A.U.
    Inventor: Mary Ellen Rybak
  • Antitumoral Treatments
    Publication number: 20090227490
    Abstract: Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies.
    Type: Application
    Filed: April 30, 2009
    Publication date: September 10, 2009
    Applicant: Pharma Mar, S.A.U.
    Inventors: Joseph R. Bertino, Debabrata Barnejee, Saydam Guray, Jose Jimeno, Glynn Thomas Faircloth
  • Antitumoral treatments
    Patent number: 7576188
    Abstract: Aplidine and aplidine analogues are of use for the treatment of cancer, in particular in the treatment of leukemias and lymphomas, especially in combination therapies.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: August 18, 2009
    Assignee: Pharma Mar, S.A.U.
    Inventors: Joseph R. Bertino, Debabrata Barnejee, Saydam Guray, José Jimeno, Glynn Thomas Faircloth
  • Total synthesis of myriaporones
    Patent number: 7521478
    Abstract: Compounds of the general formula (I) or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR?3, SOR?, SO2X, C(?O)R?, C(?O)OR?, C(?O)NR?, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R? is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R? is selected from the group consisting of H, OH, OR?, OCOR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, N(COR?)2, NHSO2R?, CN, halogen, C(?O)H, C(?O)R?, CO2H, CO2R?, CH2OR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substit
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: April 21, 2009
    Assignee: Pharma Mar, S.A.U.
    Inventors: Carlos del Pozo Losada, Andres Francesch, Carmen Cuevas Marchante, Marta Perez Alvarez
  • Antitumoral compounds
    Patent number: 7507708
    Abstract: The present invention is directed to new kahalalide antitumoral compounds, in particular to analogues of kahalalide F, useful as antitumoral, antiviral, antifungal agents and in the treatment of psoriasis.
    Type: Grant
    Filed: October 20, 2003
    Date of Patent: March 24, 2009
    Assignee: Pharma Mar, S.A.U.
    Inventors: Glynn Thomas Faircloth, Maria del Carmen Cuevas Marchante
  • Kahalalide Compositions
    Publication number: 20080318848
    Abstract: The present invention is directed to new kahalalide antitumoral compounds, in particular to analogs of kahalalide F, useful as antitumoral, antiviral, and antifungal agents.
    Type: Application
    Filed: January 25, 2008
    Publication date: December 25, 2008
    Applicant: Pharma Mar S.A.U.
    Inventors: Glynn Faircloth, Maria del Carmen Cuevas Marchante
  • Total Synthesis of Myriaporones
    Publication number: 20080269511
    Abstract: Compounds of the general formula (I) or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR?3, SOR?, SO2X, C(?O)R?, C(?O)OR?, C(?O)NR?, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R? is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R? is selected from the group consisting of H, OH, OR?, OCOR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, N(COR?)2, NHSO2R?, CN, halogen, C(?O)H, C(?O)R?, CO2H, CO2R?, CH2OR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substit
    Type: Application
    Filed: September 1, 2005
    Publication date: October 30, 2008
    Applicant: Pharma Mar S.A.U.
    Inventors: Carlos del Pozo Losada, Andres Francesch Solloso, Carmen Cuevas Marchante, Marta Perez Alvarez
  • Antitumoral analogs of lamellarins
    Patent number: 7396837
    Abstract: New lamellarins are provided of the general formula III or a pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: July 8, 2008
    Assignee: Pharma Mar, S.A.U.
    Inventors: Christian Bailly, Andrés Francesch, Maria Cristina Mateo Urbano, José Antonio Jiménez Guerrero, Alfredo Pastor Del Castillo, Carmen Cuevas Marchante
  • Kahalalide Compositions
    Publication number: 20080119397
    Abstract: The present invention is directed to new kahalalide antitumoral compounds, in particular to analogs of kahalalide F, useful as antitumoral, antiviral, and antifungal agents.
    Type: Application
    Filed: January 25, 2008
    Publication date: May 22, 2008
    Applicant: Pharma Mar S.A.U
    Inventors: Glynn Faircloth, Maria Cuevas Marchante
  • Total Synthesis of Myriaporones
    Publication number: 20080103320
    Abstract: Compounds of the general formula (I) or pharmaceutically acceptable salt, derivative, prodrug or stereoisomer thereof are provided: wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR?3, SOR?, SO2X, C(?O)R?, C(?O)OR?, C(?O)NR?, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aryl, heteroaryl or aralkyl; the group R? is selected from substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, aminoalkyl, aryl, aralkyl and heterocyclic groups; and the group R? is selected from the group consisting of H, OH, OR?, OCOR?, SH, SR?, SOR?, SO2R?, NO2, NH2, NHR?, N(R?)2, NHCOR?, N(COR?)2, NHSO2R?, CN, halogen, C(=O)H, C(=O)R?, CO2H, CO2R?, CH2OR, substituted or unsubstituted alkyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkylidene, substituted or unsubstituted alkynyl, substitut
    Type: Application
    Filed: September 1, 2005
    Publication date: May 1, 2008
    Applicant: Pharma Mar S.A.U.
    Inventors: Carlos del Pozo Losada, Andres Francesch Solloso, Carmen Cuevas Marchante, Marta Perez Alvarez
  • Kahalalide Compositions for the Treatment of Psoriasis
    Publication number: 20080090757
    Abstract: Kahalalide compounds, in particular kahalalide F, are of use in a method to treat a mammal suffering from skin disease such as psoriasis while avoiding toxicity and leading to clinical improvement.
    Type: Application
    Filed: December 4, 2007
    Publication date: April 17, 2008
    Applicant: PHARMA MAR, S.A.U.
    Inventor: Miguel Izquierdo Delso
  • Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
    Patent number: 7323444
    Abstract: Kahalalide compounds, in particular kahalalide F, are of use in a method to treat a mammal suffering from skin disease with avoiding toxicity and leading to clinical improvement.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: January 29, 2008
    Assignee: Pharma Mar, S.A.U.
    Inventor: Miguel Angel Izquierdo Delso
  • Sequences from an endosymbiont and their uses
    Patent number: 7309601
    Abstract: rDNA corresponding to an endosymbiotic bacteria associated with Ecteinascidia turbinata has been identified. The bacterium appears to be responsible for the biosynthesis of ecteinascidin compounds. The 16S rDNA sequence corresponding to Candidatus Endoecteinascidia frumentensis SEQ ID NO: 1 has been deposited in GeneBank with the accession number AY054370.
    Type: Grant
    Filed: August 13, 2003
    Date of Patent: December 18, 2007
    Assignee: Pharma Mar, S.A.U.
    Inventors: Beatriz Pérez Esteban, Tomás Aparicio Pèrez, Ana Velasco Iglesias, Rubén Henriquez Peláez, Rosario Muñoz Moreno, Claire Moss, Douglas McKenzie
  • Combination
    Publication number: 20070190164
    Abstract: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of capecitabine is administered in combination with ET-743 in a dose range between 0.75 and 1.4 mg/M2 for Et-743. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with capecitabine in a dose range between 1500 to 2500 mg/m/day for capecitabine.
    Type: Application
    Filed: November 15, 2004
    Publication date: August 16, 2007
    Applicant: PHARMA MAR, S.A.U.
    Inventor: Mary Rybak
  • Combined use of ecteinascidin-743 and platinum antineoplastic compounds
    Publication number: 20070128201
    Abstract: ET-743 can be used to mitigate resistance to and potentiate the cytotoxic effects of a platinum coordination complex anti-neoplastic agent in a human cancer patient.
    Type: Application
    Filed: June 1, 2004
    Publication date: June 7, 2007
    Applicant: Pharma Mar, S.A.U.
    Inventors: Maurizio D'Incalci, Luca Gianni, Raffaella Giavazzi, Margarita Martin, Ian Judson, Jose Donaque, Cristiana Sessa
  • Combination therapy comprising the use of et-743 and doxorubicin for treating cancer
    Publication number: 20070082856
    Abstract: Methods of treating a human body for cancer are provided. In one aspect, a therapeutic amount of doxorubicin is administered in combination with ET-743 in a dose range between 0.5 and 1 mg/m2. In a related aspect, an effective therapeutic amount of ET-743 is administered in combination with doxorubicin in a dose range between 40 and 80 mg/m2.
    Type: Application
    Filed: November 12, 2004
    Publication date: April 12, 2007
    Applicant: Pharma Mar, S.A.U.
    Inventors: Luca Gianni, Maurizio D'Incalci, Filippo de Braud, Silvia Marsoni, Jose Donaque, Luis Lazaro